Recent breakthroughs in anti-Abeta immunotherapy for Alzheimer’s have shown disease-modifying potential, with vaccination emerging as a promising approach, as AC Immune’s Marija Vukicevic, Yves Kremer, Marie Kosco-Vilbois and Andrea Pfeifer explain.
From Abeta
peptides to toxic oligomers and plaque. [Credit AC Immune]
After decades of research efforts, targeting extracellular amyloid beta (Abeta) has recently been shown to have a disease-modifying effect with anti-Abeta monoclonal antibodies (mAb) making breakthroughs in Phase III trials and clinically validating the amyloid hypothesis. Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline.
This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.
Key learning points:
Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
Learn about ITM’s implementation journey and considerations when evaluating the technology
Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).
Don’t miss your chance to learn from experts in the industry –Register for FREE
Limitations of monoclonal antibody therapies
Regulatory approvals from the US Food and Drug Administration (FDA) for aducanumab and lecanemab – and likely very soon for donanemab also – opened a route for different therapeutic modalities and other relevant disease targets, such as tau. Treatment with the mAbs delayed cognitive decline by 2.6 months (aducanumab) and the more meaningful amounts of 5.1 months for lecanemab and 5.5 months for donanemab.1
However, infusions of different doses of mAbs resulted in dose-dependent amyloid-related imaging abnormalities vasogenic edema (ARIA-E) of varying degrees (in up to 41 percent, 26.7 percent and 14.3 percent of patients injected with, respectively, aducanumab, donanemab and lecanemab). These ARIA-E effects are attributed to very high doses of mAbs leading to peak levels as measured in plasma and cerebrospinal fluid (CSF). These peaks are rapidly followed by a decrease to the minimal (trough) levels, after which the mAbs are re-infused, either monthly (donanemab) or every second week (lecanemab), in order to maintain efficacy.
These mAb treatments are further complicated by anti-drug antibody (ADA) responses in patients. For lecanemab this appears to be a relatively low-level response with little impact on treatment.2 However, for donanemab more than 90 percent of patients developed anti-drug antibodies three months after the first dose and these persisted for three months after the last dose.3 This high level of ADA induction may explain the reductions in treatment effects, despite high injected doses of the antibody.
While new positive clinical data with anti-Abeta mAbs signal tremendous advancement and proof‑of-concept for the whole field, it is believed that the observed effects could still be improved and optimised in terms of greater clinical benefits, lower side effects and enhanced treatment convenience.
Active anti-Abeta immunotherapies
In the 2000s, the concept of active immunotherapy targeting Abeta in Alzheimer’s patients was assessed with the ELAN vaccine (AN1792), consisting of full-length aggregated Abeta 1-42 peptide mixed with the QS21 adjuvant. The vaccination of patients with AN1792 led to the activation of their immune systems, which started producing endogenous anti-Abeta antibodies. In 19.7 percent of immunised patients who developed high anti-Abeta antibody titers, the lowering of brain Abeta was measured and hints of clinical efficacy were observed.4
Vaccines compared to passive immunotherapy [Credit AC Immune]
However, the clinical trial was terminated early, as six percent of patients developed meningoencephalitis, likely due to the infiltration of Abeta-specific T cells in the brain producing inflammation.5 The lesson learned from this trial was that vaccines containing Abeta T-cell epitopes should be avoided. The next generation of active immunotherapies was based on Abeta peptides with the capacity to activate only Abeta-specific B cells, but not T cells. This was achieved by using the N-terminal part of Abeta that is devoid of dominant Abeta T-cell epitopes.6
The proof-of-concept from the mAbs shows the relevance of immunologically targeting extracellular toxic Abeta species but the aforementioned drawbacks of this approach must be considered. Therefore, active immunotherapy to trigger the immune system to produce sustained levels of endogenous antibodies has now become far more attractive.
There are multiple advantages of active immunotherapy through vaccination (see Table 1):
*amyloid-related imaging abnormalities
The human immune system is activated to produce a long-lasting polyclonal antibody response that has a broader epitope coverage (eg, specific for multiple toxic species) than the mAbs, which each target a single epitope.
Once the initial polyclonal response is induced, it can be restored and maintained with occasional immunisations (eg, every six to 12 months). Conversely, mAb infusions lead to high peak levels in the circulation, which subsequently decrease rapidly, necessitating repeat injections every two to four weeks.
Antibody responses induced with active immunotherapy are polyclonal and self‑optimised in their specificity towards the pathological target relevant for human pathology, through the process of affinity maturation.
The constant and steadily maintained antibody levels of the polyclonal antibody response carry a lower risk of inducing ARIA-E, as compared to the rapid extreme fluctuations in antibody levels experienced with mAb therapies.
Patient convenience is far greater with a vaccine administration schedule requiring only a limited number of injections each year, as compared to burdensome intravenous infusions every few weeks for mAbs.
Active immunotherapy through vaccination has a far lower cost than mAb-based therapies, representing an important decrease of economic burden for healthcare systems at a global scale.
Anti-Abeta active immunotherapies currently in clinical development
Currently, there are several anti-Abeta active immunotherapies in clinical development (Table 2).
AC Immune’s vaccine candidate, ACI‑24.060, is a liposomal active immunotherapy, presenting the Abeta 1-15 peptide in a unique, conformationally‑restricted manner such that the induced antibody response shows very high specificity towards the pathological Abeta species such as oligomers and pyroglutamate Abeta.7 It is currently being evaluated in a Phase Ib/IIa clinical study, demonstrating to date a good safety profile. ALZ‑101 (Alzinova) immunotherapy, currently in a Phase IIb trial, contains hexameric, conformationally-restricted Abeta1-42 peptides mixed with alum adjuvant, leading to the production of antibodies preferentially binding to the oligomeric forms of Abeta.
ABvac40 (Araclon Biotech) is a KLH-conjugate bound to the C-terminal region of Abeta (33-40) and induces antibodies binding to different forms of Abeta, including monomers, oligomers and plaques. While favourable safety has been reported up to the Phase II, the relevance of targeting the C-terminal portion of Abeta still needs to be confirmed. In addition, a KLH protein carrier cannot be easily used in marketed products due to the significant variability of this natural material.
AV-1959D from Nuravax is a DNA-based therapeutic, containing Abeta1-11 sequence bound to multiple T-cell helper epitopes.
UB-311 from Vaxxinity is composed of two copies of Abeta1-14 peptide, each bound to a different T-cell helper peptide and further mixed with alum and CpG adjuvants. UB-311 has demonstrated favourable safety in Phase I and II studies and suggested in Phase II a potential improvement of cognitive function.8
[Editor’s note: Since this article was written in June 2023, results from a randomised, double-blind, placebo-controlled, Phase IIa study of UB-311 have been published in the Lancet. The Phase IIa study met its primary objectives of demonstrating safety, tolerability, and immunogenicity.]
Taken together, the accumulating data for vaccines demonstrates general favourable safety, including the absence of significant ARIA-E
Finally, ALZN-002 (Alzamend Neuro), which has received regulatory approval to initiate a clinical study, is a cell-based therapy, based on patient-derived dendritic cells pulsed with a mutated Abeta1-42 peptide. This approach has been taken to generate new T-cell epitopes to improve immunogenicity. However, while it seems that the mutations inactivate some of the Abeta T-cell epitopes, it is unclear whether other Abeta T-cell epitopes are still present and thus could be potentially harmful in this therapeutic approach.
Taken together, the accumulating data for vaccines demonstrates general favourable safety, including the absence of significant ARIA-E. Very different approaches are being assessed (eg, liposomes, conjugates, peptide-based, cell‑based) to maximise the level of the induced antibody response, which is particularly important in elderly patients with declining efficiency of the immune system. Some approaches are also focused on targeting specific Abeta conformations (eg, ACI-24.060, ALZ-101). We eagerly await further clinical trial results for the different vaccine candidates to see which of the approaches has the highest potential to succeed in modifying the course of disease.
Active immunotherapies provide a broad range of applications
Independent of the approach used, a question frequently arises regarding how to use active anti‑Abeta immunotherapies, considering that part of the population will already be treated with the approved, or soon-to-be approved, mAb-based therapies. Following mAb treatment discontinuation, Abeta plaques reaccumulate at a slow rate. Modelling for both lecanemab and donanemab suggests that after treatment discontinuation, brain amyloid reaccumulation to baseline levels is slow with a recovery half‑life of approximately four years. However, other biomarkers such as plasma Abeta1-42/1-40 ratio and p-tau181 return to baseline levels faster than amyloid.9 In these cases, it seems logical to envisage vaccination as a maintenance active immunotherapy following mAb therapy. Once the pathological Abeta has been cleared by mAb, antibodies targeting pathological Abeta induced with the active immunotherapy would potentially act by immediately removing newly‑formed pathological components and preventing the establishment of new amyloid plaques.
As mentioned, the clinical benefit of currently available anti-Abeta mAbs is limited, delaying cognitive decline by a few to several months. This could certainly be improved by starting the treatment earlier in the course of disease, before the pathology becomes established. However, this would be difficult to achieve with the costly mAb treatments, where we know that payors typically only accommodate treating an existing pathology as opposed to preventing an imminent pathology.
In this context, active immunotherapy through vaccination could play a significant role. Being more convenient for the patients, less expensive and, therefore, more accessible to the broader population, active immunotherapy could be applied in at-risk populations, before the development of symptoms, or even in a more global population in a fully preventative setting.
Active immunotherapy for other diseases
All these options offer avenues for a more robust programme of treatment and prevention of Alzheimer’s disease. But its power does not end here. The same concept has started to be explored for other neurodegenerative disorders, such as Parkinson’s disease. More globally, where the accumulation of pathological forms of ‘self proteins’ causes disease, the active immunotherapy approach could be considered for different kinds of chronic diseases to modify their course and improve patients’ lives.
About the authors
Marija Vukicevic, PhD
After obtaining her master’s degree in Molecular Biology and Biotechnology at the Faculty of Biology, University of Belgrade, Serbia, Marija earned her PhD in Neurosciences at University of Lausanne, Switzerland, working on neuronal ion channels. Continuing her work in the neuroscience field, she carried out further postdoctoral research working on neuronal stem cells at the University of Geneva. From there her research shifted to the immunology field, specialising in haematopoietic stem cell transplantation and vaccinology at Geneva University Hospitals. Marija joined AC Immune SA in Lausanne in 2011 as a research scientist and subsequently became a team leader in vaccine discovery. Since 2019, she has been Head of Vaccines and Immunoanalytical Sciences at AC Immune.
Yves Kremer, PhD
After obtaining his PhD in Neuroscience at the Ecole Normale Supérieure de Paris, France, Yves worked on sensory processing at the Ecole Polytechnique Fédérale in Lausanne (EPFL), and dopaminergic networks underlying reward-based learning at the University of Geneva, Switzerland. He then worked as a clinical scientist for a med tech company developing spinal cord stimulation for people living with spinal cord injury. Yves joined AC Immune in 2020 and is now Manager, Investor Relations and Communications.
Marie Kosco-Vilbois, PhD
Marie Kosco-Vilbois joined AC Immune as Chief Scientific Officer in 2019. She has extensive experience in the biopharmaceutical industry and previously served as Chief Scientific Officer for Novimmune from 2005. Prior to joining Novimmune in 2002, she was Head of Immunology and Preclinical Pharmacology at the Serono Pharmaceutical Research Institute, a Senior Scientist and then Head of Immunology at the Glaxo Wellcome Research Institute in Geneva, and a Scientific Member of the Basel Institute for Immunology. Dr Kosco-Vilbois holds a PhD in Anatomy and Immunology from the Medical College of Virginia/Virginia Commonwealth University School of Medicine, US.
Andrea Pfeifer, PhD
In 2003, Andrea Pfeifer co-founded AC Immune SA. She is currently CEO and successfully led the IPO on Nasdaq in 2016. She currently serves as the Chair of Investment Fund BioMedInvest and AB2 Bio SA and is a member of the Supervisory Board of Symrise AG. Andrea is also a key member of the CEOi initiative on Alzheimer’s Disease and the Davos Alzheimer’s Collaborative. In 2021, she was awarded the first SEF.WomenAward for CEO of the Year by the Swiss Economic Forum. Andrea holds a PhD in Toxicology (Cancer Research) from the University of Würzburg, Germany and is a registered Toxicologist and Pharmacist.
References
Hendrix S. 2023 AD/PD Conference. An overview of clinical trial results in Alzheimer’s Disease in the past 2 decades with a focus on time savings.
Landry I, Kanekiyo M, Aluri J, et al. 2022 Alzheimer’s Association International Conference. Lecanemab (BAN2401) infusion reactions and immunogenicity: results from randomized phase 2 study and an open-label extension.
Lowe SL, Duggan Evans C, et al. 2021 Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. Journal of Prevention of Alzheimer’s Disease. 2021;1–11.
Vellas B, Black R, Thal L, et al. 2009. Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders Current Alzheimer Research. 2009;6(2):144–51.
Gilman S, Koller M, Black RS, et al. Clinical effects of a immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9):1553–62.
Monsonego A, Zota V, Karni A, et al. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer’s disease. Journal of Clinical Investigation. 2003;112(3):415–22.
Vukicevic M, Fiorini E, Siegert S, et al. An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer’s disease: pyroglutamate amyloid beta. Brain Communications.2022;4(1).
Wang CY, et al. UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2017;3(2):262-272.
Hayato S et al. Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer’s disease. CPT Pharmacometrics Syst Pharmacol. 2022;11(12):1578-91.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.